SK17102002A3 - Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu - Google Patents

Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu Download PDF

Info

Publication number: SK17102002A3
Authority: SK; Slovakia
Prior art keywords: yloxy; phenylamino; methyl; pyridin; quinazolin
Prior art date: 2000-06-22

Application number

SK1710-2002A

Other languages

English (en)

Slovak (sk)

Inventor

John Charles Kath

Samit Kumar Bhattacharya

Joel Morris

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2001-06-14

Publication date

2004-04-06

2001-06-14 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-04-06 Publication of SK17102002A3 publication Critical patent/SK17102002A3/sk

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Plant Substances (AREA)

SK1710-2002A 2000-06-22 2001-06-14 Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu SK17102002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21313600P	2000-06-22	2000-06-22
PCT/IB2001/001046 WO2001098277A2 (en)	2000-06-22	2001-06-14	Substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number	Publication Date
SK17102002A3 true SK17102002A3 (sk)	2004-04-06

Family

ID=22793862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1710-2002A SK17102002A3 (sk)	2000-06-22	2001-06-14	Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu

Country Status (43)

Country	Link
US (2)	US6890924B2 (ru)
EP (1)	EP1292591B1 (ru)
JP (1)	JP4044839B2 (ru)
KR (1)	KR100545537B1 (ru)
CN (3)	CN1437594A (ru)
AP (1)	AP2001002192A0 (ru)
AR (1)	AR032353A1 (ru)
AT (1)	ATE288431T1 (ru)
AU (1)	AU2001264159A1 (ru)
BG (1)	BG107269A (ru)
BR (1)	BR0111548A (ru)
CA (1)	CA2413424C (ru)
CZ (1)	CZ20023951A3 (ru)
DE (1)	DE60108754T2 (ru)
DK (1)	DK1292591T3 (ru)
DZ (1)	DZ3407A1 (ru)
EA (1)	EA005525B1 (ru)
EC (1)	ECSP024393A (ru)
EE (1)	EE200200710A (ru)
ES (1)	ES2236240T3 (ru)
GE (1)	GEP20063831B (ru)
HK (1)	HK1069576A1 (ru)
HR (1)	HRP20021005A2 (ru)
HU (1)	HUP0301120A2 (ru)
IL (1)	IL152985A0 (ru)
IS (1)	IS6616A (ru)
MA (1)	MA26914A1 (ru)
MX (1)	MXPA02012870A (ru)
MY (1)	MY127181A (ru)
NO (1)	NO20026166L (ru)
NZ (1)	NZ522568A (ru)
OA (1)	OA12291A (ru)
PA (1)	PA8520301A1 (ru)
PE (1)	PE20020257A1 (ru)
PL (1)	PL359557A1 (ru)
PT (1)	PT1292591E (ru)
SK (1)	SK17102002A3 (ru)
SV (1)	SV2002000504A (ru)
TN (1)	TNSN01091A1 (ru)
UA (1)	UA73990C2 (ru)
WO (1)	WO2001098277A2 (ru)
YU (1)	YU95102A (ru)
ZA (1)	ZA200210231B (ru)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7772432B2 (en) *	1991-09-19	2010-08-10	Astrazeneca Ab	Amidobenzamide derivatives which are useful as cytokine inhibitors
RS49779B (sr) *	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1117653B1 (en) *	1998-10-01	2003-02-05	AstraZeneca AB	Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
CA2413424C (en) *	2000-06-22	2007-10-02	Pfizer Products Inc.	Substituted bicyclic derivatives for the treatment of abnormal cell growth
CN1264824C (zh) *	2001-02-21	2006-07-19	三菱制药株式会社	喹唑啉衍生物
US20030144308A1 (en) *	2001-09-24	2003-07-31	Bauer Paul H.	Fructose 1,6-bisphosphatase inhibitors
RU2004116345A (ru) *	2001-11-30	2005-03-27	Пфайзер Продактс Инк. (Us)	Способы получения замещенных бициклических производных, полезных для лечения патологического роста клеток
BR0214499A (pt) *	2001-12-12	2005-05-10	Pfizer Prod Inc	Derivados de quinazolina para o tratamento do crescimento anormal das células
EA007412B1 (ru) *	2001-12-12	2006-10-27	Пфайзер Продактс Инк.	Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ES2400339T3 (es)	2002-07-15	2013-04-09	Symphony Evolution, Inc.	Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US7488823B2 (en) *	2003-11-10	2009-02-10	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1567506A4 (en)	2002-11-20	2007-06-20	Array Biopharma Inc	CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
AU2003303045A1 (en) *	2002-12-18	2004-07-09	Pfizer Products Inc.	4-anilino quinazoline derivatives for the treatment of abnormal cell growth
PL377533A1 (pl) *	2002-12-19	2006-02-06	Pfizer Products Inc.	Kompleksy E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylopirydyn-3-yloksy)-fenyloamino]-chinazolin-6-ylo}-allilo)-acetamidu, sposób ich wytwarzania i zastosowanie
RS20050652A (en) *	2003-04-09	2007-11-15	Pfizer Products Inc.,	Process for the preparation of n- (((pyridinyloxy)- phenylamino)quinazolinyl)- alyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
JP2007501854A (ja) *	2003-05-27	2007-02-01	ファイザー・プロダクツ・インク	受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
WO2006074147A2 (en)	2005-01-03	2006-07-13	Myriad Genetics, Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
NZ544472A (en) *	2003-07-03	2009-04-30	Myriad Genetics Inc	Compounds and therapeutical use thereof
BRPI0412664A (pt) *	2003-07-15	2006-09-26	Ca Nat Research Council	método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
CA2535614C (en) *	2003-08-14	2009-12-22	Array Biopharma Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
RU2328287C2 (ru) *	2003-08-18	2008-07-10	Пфайзер Продактс Инк.	Схема приема erbb2 противоопухолевых агентов
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
EP1673085B1 (en)	2003-09-26	2011-11-09	Exelixis, Inc.	C-met modulators and methods of use
JP2007510708A (ja) *	2003-11-06	2007-04-26	ファイザー・プロダクツ・インク	癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
DE602005010824D1 (de)	2004-02-03	2008-12-18	Astrazeneca Ab	Chinazolinderivate
US20050192298A1 (en) *	2004-02-27	2005-09-01	Pfizer Inc	Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
CA2573821A1 (en)	2004-07-16	2006-01-26	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
CN101010304A (zh) *	2004-09-01	2007-08-01	三菱制药株式会社	分子伴侣功能调节剂
WO2006071079A1 (en) *	2004-12-29	2006-07-06	Hanmi Pharm. Co., Ltd.	Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko)	2004-12-29	2007-07-04	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
EP2444421A1 (en)	2005-04-26	2012-04-25	Pfizer Inc.	P-Cadherin antibodies
WO2006129168A2 (en) *	2005-06-03	2006-12-07	Pfizer Products Inc.	Bicyclic derivatives for the treatment of abnormal cell growth
WO2006129163A1 (en) *	2005-06-03	2006-12-07	Pfizer Products Inc.	Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
SI1933871T1 (sl)	2005-09-07	2013-10-30	Amgen Fremont Inc.	Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1
DK2090575T3 (da) *	2005-11-15	2011-05-23	Array Biopharma Inc	Fremgangsmåder og mellemprodukter til fremstillingen af N4 phenylquinazolin-4-aminderivater
GB0526552D0 (en) *	2005-12-29	2006-02-08	Morvus Technology Ltd	New use
KR20090007792A (ko)	2006-05-09	2009-01-20	화이자 프로덕츠 인크.	시클로알킬아미노산 유도체 및 이들의 제약 조성물
WO2008002039A1 (en) *	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Quinazoline derivatives for inhibiting the growth of cancer cell
KR20090077914A (ko) *	2006-09-11	2009-07-16	쿠리스 인코퍼레이션	항증식제로서의 다작용성 소분자
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033749A2 (en) *	2006-09-11	2008-03-20	Curis, Inc.	Quinazoline based egfr inhibitors containing a zinc binding moiety
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja)	2006-12-12	2010-04-02	武田薬品工業株式会社	縮合複素環化合物
AU2008212999A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2851091B1 (en)	2007-04-13	2017-12-27	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer resistant to ERBB therapeutics
KR20100111291A (ko)	2008-02-07	2010-10-14	베링거 인겔하임 인터내셔날 게엠베하	스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
PE20091580A1 (es)	2008-03-12	2009-11-05	Takeda Pharmaceutical	Compuesto heterociclico fusionado
US8426430B2 (en) *	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
JP5539351B2 (ja)	2008-08-08	2014-07-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TWI447108B (zh)	2009-01-16	2014-08-01	Exelixis Inc	Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2772194A1 (en)	2009-09-01	2011-03-10	Pfizer Inc.	Benzimidazole derivatives
US9265739B2 (en)	2010-06-02	2016-02-23	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en)	2010-06-02	2011-12-08	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to her2/neu receptor complex
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
JP5802756B2 (ja)	2010-10-20	2015-11-04	ファイザー・インク	スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
AP2014007475A0 (en)	2011-09-22	2014-02-28	Pfizer	Pyrrolopyrimidine and purine derivates
CN102872018B (zh) *	2012-10-23	2015-07-15	广州市恒诺康医药科技有限公司	酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en)	2014-04-10	2015-10-15	Pfizer Inc.	Dihydropyrrolopyrimidine derivatives
MA49708A (fr)	2014-04-30	2020-06-03	Pfizer	Dérivés de dihétérocycle liés à cycloalkyle
KR101589632B1 (ko)	2014-06-03	2016-02-01	한국과학기술연구원	항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en)	2014-06-30	2016-01-07	Pfizer Inc.	Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CN107922609B (zh)	2015-07-01	2020-04-24	加州理工学院	基于阳离子粘酸聚合物的递送系统
WO2017009751A1 (en)	2015-07-15	2017-01-19	Pfizer Inc.	Pyrimidine derivatives
EP3424928A4 (en) *	2016-03-01	2019-10-09	Shanghai Pharmaceuticals Holding Co., Ltd.	HETEROCYCLIC NITROGEN COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
US20190381188A1 (en)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
LT3853220T (lt)	2018-09-18	2024-03-12	F. Hoffmann-La Roche Ag	Chinazolino dariniai kaip antinavikiniai preparatai
CN118715216A (zh) *	2022-03-28	2024-09-27	江苏恒瑞医药股份有限公司	含氮杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (ru) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
US6225318B1 (en)	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
ZA986732B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2002527436A (ja)	1998-10-08	2002-08-27	アストラゼネカアクチボラグ	キナゾリン誘導体
JP3270834B2 (ja) *	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
CA2413424C (en) *	2000-06-22	2007-10-02	Pfizer Products Inc.	Substituted bicyclic derivatives for the treatment of abnormal cell growth

2001
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active IP Right Cessation
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en active Application Filing
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166L/no unknown
2005
- 2005-03-11 HK HK05102099A patent/HK1069576A1/xx not_active IP Right Cessation
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA200201277A1 (ru)	2003-06-26
MA26914A1 (fr)	2004-12-20
GEP20063831B (en)	2006-05-25
EP1292591A2 (en)	2003-03-19
ZA200210231B (en)	2004-02-12
TNSN01091A1 (fr)	2005-11-10
DE60108754T2 (de)	2005-06-23
OA12291A (en)	2004-03-18
YU95102A (sh)	2005-11-28
HUP0301120A2 (hu)	2003-08-28
WO2001098277A3 (en)	2002-06-13
PA8520301A1 (es)	2003-06-30
WO2001098277A2 (en)	2001-12-27
DE60108754D1 (de)	2005-03-10
IS6616A (is)	2002-11-14
HRP20021005A2 (en)	2004-02-29
NO20026166D0 (no)	2002-12-20
CA2413424C (en)	2007-10-02
EP1292591B1 (en)	2005-02-02
CN1576275A (zh)	2005-02-09
PT1292591E (pt)	2005-06-30
IL152985A0 (en)	2003-06-24
UA73990C2 (en)	2005-10-17
AP2001002192A0 (en)	2002-12-21
CN1330640C (zh)	2007-08-08
EA005525B1 (ru)	2005-04-28
BR0111548A (pt)	2003-05-06
PE20020257A1 (es)	2002-04-08
CA2413424A1 (en)	2001-12-27
KR20030016303A (ko)	2003-02-26
BG107269A (bg)	2003-06-30
US6890924B2 (en)	2005-05-10
US20020169165A1 (en)	2002-11-14
DZ3407A1 (ru)	2001-12-27
US7332493B2 (en)	2008-02-19
HK1069576A1 (en)	2005-05-27
EE200200710A (et)	2004-06-15
MXPA02012870A (es)	2003-05-14
AU2001264159A1 (en)	2002-01-02
PL359557A1 (en)	2004-08-23
SV2002000504A (es)	2002-10-24
CN101348467A (zh)	2009-01-21
JP2004501139A (ja)	2004-01-15
NZ522568A (en)	2004-12-24
ATE288431T1 (de)	2005-02-15
KR100545537B1 (ko)	2006-01-25
JP4044839B2 (ja)	2008-02-06
MY127181A (en)	2006-11-30
CZ20023951A3 (cs)	2004-01-14
US20050159435A1 (en)	2005-07-21
NO20026166L (no)	2002-12-20
ECSP024393A (es)	2003-02-06
ES2236240T3 (es)	2005-07-16
CN1437594A (zh)	2003-08-20
DK1292591T3 (da)	2005-05-30
AR032353A1 (es)	2003-11-05

Publication	Publication Date	Title
SK17102002A3 (sk)	2004-04-06	Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu
US7585869B2 (en)	2009-09-08	Substituted heterocylces for the treatment of abnormal cell growth
KR100816166B1 (ko)	2008-03-21	항증식제로서 유용한 신규한 벤조이미다졸린 유도체
JP4181502B2 (ja)	2008-11-19	異常な細胞増殖を治療するためのキナゾリン誘導体
EP1147093B1 (en)	2007-04-11	Substituted bicyclic derivatives useful as anticancer agents
US20080194596A1 (en)	2008-08-14	Therapeutic Combination Including a Selective Erbb2 Inhibitor
US20050101618A1 (en)	2005-05-12	Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
JP4220388B2 (ja)	2009-02-04	異常な細胞増殖を処置するための置換された二環式誘導体の製造方法

Legal Events

Date	Code	Title	Description
2010-04-07	FB9A	Suspension of patent application procedure